Skip to main content
Retour
HLN logo

Haleon plc

Qualité des données : 100%
HLN
NYSE Healthcare Drug Manufacturers - Specialty & Generic
9,93 €
▼ 0,14 € (-1,39%)
Cap. Boursière : 44,22B
Également cotée sous HLNCF OTC
Fourchette du Jour
9,90 € 10,10 €
Fourchette 52 Semaines
8,71 € 11,42 €
Volume
12 392 873
Moyenne 50J / 200J
10,51 € / 9,91 €
Clôture Précédente
10,07 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E 27,1 0,4
P/B 2,7 2,9
ROE % 10,0 3,7
Net Margin % 15,1 3,9
Rev Growth 5Y % 3,1 10,0
D/E 0,5 0,2

Objectif de Cours des Analystes

Hold
10,20 € +2.7%
P/E Prévisionnel
24,1
BPA Prévisionnel
0,41 €
Croissance BPA (est.)
+0,0%
CA Est.
11 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 0,56 €
0,55 € – 0,57 €
13 B 2
FY2029 0,55 €
0,54 € – 0,56 €
13 B 4
FY2028 0,50 €
0,45 € – 0,54 €
12 B 6

Points Clés

Revenue grew 3,11% annually over 5 years — modest growth
ROE of 10,01% — decent returns on equity
Net margin of 15,11% shows strong profitability
Generating 1,97B in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 7,07%
Cash machine — converts 120,88% of earnings into free cash flow

Croissance

Revenue Growth (5Y)
3,11%
Revenue (1Y)-3,96%
Earnings (1Y)13,07%
FCF Growth (3Y)5,70%

Qualité

Return on Equity
10,01%
ROIC7,27%
Net Margin15,11%
Op. Margin22,44%

Sécurité

Debt / Equity
0,52
Current Ratio0,92
Interest Coverage7,28

Valorisation

P/E Ratio
27,12
P/B Ratio2,70
EV/EBITDA21,27
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -3,96% Revenue Growth (3Y) -2,30%
Earnings Growth (1Y) 13,07% Earnings Growth (3Y) 24,67%
Revenue Growth (5Y) 3,11% Earnings Growth (5Y) 4,07%
Profitability
Revenue (TTM) 10,79B Net Income (TTM) 1,63B
ROE 10,01% ROA 5,01%
Gross Margin 64,77% Operating Margin 22,44%
Net Margin 15,11% Free Cash Flow (TTM) 1,97B
ROIC 7,27% FCF Growth (3Y) 5,70%
Safety
Debt / Equity 0,52 Current Ratio 0,92
Interest Coverage 7,28 Dividend Yield 0,02%
Valuation
P/E Ratio 27,12 P/B Ratio 2,70
P/S Ratio 4,10 PEG Ratio 1,65
EV/EBITDA 21,27 Dividend Yield 0,02%
Market Cap 44,22B Enterprise Value 51,49B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 10,79B 11,23B 11,30B 10,86B 9,55B
Net Income 1,63B 1,44B 1,05B 1,06B 1,39B
EPS (Diluted) 0,36 0,32 0,24 0,24 0,30
Gross Profit 6,99B 6,95B 6,96B 6,58B 5,95B
Operating Income 2,42B 2,21B 2,00B 1,83B 1,64B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 32,57B 34,32B 34,06B 34,82B 34,45B
Total Liabilities 16,12B 18,09B 17,33B 18,36B 7,97B
Shareholders' Equity 16,40B 16,17B 16,61B 16,33B 26,36B
Total Debt 8,59B 10,10B 9,46B 10,44B 991,00M
Cash & Equivalents 1,32B 2,20B 1,04B 684,00M 414,00M
Current Assets 4,54B 5,72B 4,82B 4,06B 5,25B
Current Liabilities 4,92B 5,81B 4,64B 4,37B 4,24B